US StockDetailed Quotes

Provided by Tiger Fintech (Singapore) Pte. Ltd.

Talphera Inc.

0.4800

+0.0000

Volume:17.84K

Turnover:8.75K

Market Cap:8.21M

PE:-0.95

High:0.5000

Open:0.4803

Low:0.4711

Close:0.4800

Loading ...

Overview Company News Filings

Talphera Price Target Maintained With a $6.00/Share by HC Wainwright & Co.

BRIEF-Talphera Expected To Provide Capital Through Target Completion Of Nephro Study In Q4 Of 2025

Talphera Inc reports results for the quarter ended December 31 - Earnings Summary

Talphera: Expected to Provide Capital Through Target Completion of Nephro Study in Q4 of 2025

THOMSON REUTERS

Talphera Q4 2024 GAAP EPS $(0.07) Beats $(0.16) Estimate

Talphera to Reduce Size of Renal Replacement Therapy Study, Enters Private Placement; Shares Fall

MT Newswires Live

Talphera Inc - Talphera Believes Nephro Crrt Study Should Be Completed by End of 2025

THOMSON REUTERS

Talphera Announces Agreement With the FDA to Reduce the Nephro Crrt Study Size to 70 Patients From 166 and a Private Placement Financing Priced at-the Market of up to $14.8 Million

THOMSON REUTERS

Talphera Inc expected to post a loss of 16 cents a share - Earnings Preview

Talphera Inc expected to post a loss of 16 cents a share - Earnings Preview

Talphera reaches agreement with FDA in Nephro CRRT study

BRIEF-Talphera Announces Agreement With The FDA For Prior Approval Supplement Review To Reduce The Number Of Patients In The the NEPHRO CRRT Study

Talphera Inc: FDA Agreed to Two Additional Protocol Changes Expected to Accelerate Enrollment in Nephro Crrt Study

THOMSON REUTERS

Talphera Announces Agreement With the FDA for Prior Approval Supplement Review to Reduce the Number of Patients in the Nephro Crrt Study

THOMSON REUTERS

Talphera Announces Agreement with the FDA for Prior Approval Supplement Review to Reduce the Number of Patients in the NEPHRO CRRT Study

Talphera Inc - Receives Notice of Non-Compliance With Nasdaq Minimum Bid Price Requirement

THOMSON REUTERS

BRIEF-Talphera Receives Notice Of Non-Compliance With Nasdaq Equity Requirement

Talphera Inc - Receives Notice of Non-Compliance With Nasdaq Equity Requirement

THOMSON REUTERS

Press Release: Ascentage Pharma Appoints Ms. Marina S. Bozilenko and Dr. Debra Yu as Independent Non-Executive Directors

Talphera Third Quarter 2024 Earnings: US$0.13 loss per share (vs US$0.085 loss in 3Q 2023)

Simply Wall St.

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/TLPH/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"TLPH","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"TLPH\",,,,,undefined,":{"symbol":"TLPH","market":"US","secType":"STK","nameCN":"Talphera Inc.","latestPrice":0.48,"timestamp":1745860990032,"preClose":0.48,"halted":0,"volume":17842,"delay":0,"floatShares":16390071,"shares":17098300,"eps":-0.50314,"marketStatus":"Trading","change":0,"latestTime":"04-28 13:36:44 EDT","open":0.4803,"high":0.5,"low":0.4711,"amount":8748.60096132,"amplitude":0.060208,"askPrice":0.48,"askSize":400,"bidPrice":0.4756,"bidSize":97,"shortable":3,"etf":0,"ttmEps":-0.50314,"tradingStatus":2,"nextMarketStatus":{"tag":"Post-Mkt","tradingStatus":3,"beginTime":1745870400000},"marketStatusCode":2,"adr":0,"listingDate":1297400400000,"exchange":"NASDAQ","adjPreClose":0.48,"preHourTrading":{"tag":"盘前","latestPrice":0.4855,"preClose":0.48,"latestTime":"09:06 EDT","volume":156,"amount":75.73900152,"timestamp":1745845603442},"postHourTrading":{"tag":"盘后","latestPrice":0.4899,"preClose":0.486,"latestTime":"19:39 EDT","volume":1006,"amount":492.8127,"timestamp":1745624397453},"volumeRatio":0.723926,"impliedVol":0.9985,"impliedVolPercentile":0.056},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"TLPH\",,,,,undefined,":{"symbol":"TLPH","floatShares":16390071,"roa":"-49.35%","roe":"-117.65%","lyrEps":-0.50314,"volumeRatio":0.723926,"shares":17098300,"dividePrice":0,"high":0.5,"amplitude":0.060208,"preClose":0.48,"low":0.4711,"week52Low":0.45,"pbRate":"1.03","psRate":"29.21","week52High":1.27,"institutionHeld":0,"latestPrice":0.48,"committee":-0.609658,"eps":-0.50314,"divideRate":0,"volume":17842,"delay":0,"ttmEps":-0.50314,"open":0.4803,"prevYearClose":0.5241,"prevWeekClose":0.486,"prevMonthClose":0.495,"prevQuarterClose":0.495,"fiveDayClose":0.49,"twentyDayClose":0.586,"sixtyDayClose":0.6998},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"TLPH\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2524011890","title":"Talphera Price Target Maintained With a $6.00/Share by HC Wainwright & Co.","url":"https://stock-news.laohu8.com/highlight/detail?id=2524011890","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2524011890?lang=en_us&edition=fundamental","pubTime":"2025-04-01 20:12","pubTimestamp":1743509520,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/TLPH/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  April 01, 2025 08:12 ET (12:12 GMT)","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["TLPH"],"gpt_icon":0},{"id":"2524906488","title":"BRIEF-Talphera Expected To Provide Capital Through Target Completion Of Nephro Study In Q4 Of 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2524906488","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2524906488?lang=en_us&edition=fundamental","pubTime":"2025-04-01 06:42","pubTimestamp":1743460938,"startTime":"0","endTime":"0","summary":"BRIEF-Talphera Expected To Provide Capital Through Target Completion Of Nephro Study In Q4 Of 2025Talphera Inc TLPH.O:TALPHERA: EXPECTED TO PROVIDE CAPITAL THROUGH TARGET COMPLETION OF NEPHRO STUDY IN Q4 OF 2025Source text: ID:nPn4ynDl9aFurther company coverage: TLPH.O","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250331:nFWN3QE0WZ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["TLPH","BK4007"],"gpt_icon":0},{"id":"2524970177","title":"Talphera Inc reports results for the quarter ended December 31 - Earnings Summary","url":"https://stock-news.laohu8.com/highlight/detail?id=2524970177","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2524970177?lang=en_us&edition=fundamental","pubTime":"2025-04-01 05:01","pubTimestamp":1743454886,"startTime":"0","endTime":"0","summary":"Talphera Inc reports results for the quarter ended December 31 - Earnings SummaryTalphera Inc TLPH.OQ reported a quarterly adjusted loss of 7 cents per share for the quarter ended December 31, higher ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250331:nL5N3QE1P5:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["TLPH"],"gpt_icon":0},{"id":"2524397248","title":"Talphera: Expected to Provide Capital Through Target Completion of Nephro Study in Q4 of 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2524397248","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2524397248?lang=en_us&edition=fundamental","pubTime":"2025-04-01 04:27","pubTimestamp":1743452821,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250331:nFWN3QE0WZ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["TLPH","BK4007"],"gpt_icon":0},{"id":"2524742899","title":"Talphera Q4 2024 GAAP EPS $(0.07) Beats $(0.16) Estimate","url":"https://stock-news.laohu8.com/highlight/detail?id=2524742899","media":"Benzinga","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2524742899?lang=en_us&edition=fundamental","pubTime":"2025-04-01 04:09","pubTimestamp":1743451752,"startTime":"0","endTime":"0","summary":"Talphera (NASDAQ:TLPH) reported quarterly losses of $(0.07) per share which beat the analyst consensus estimate of $(0.16) by 56.25 percent. This is a 72 percent increase over losses of $(0.25) per share from the same","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/25/03/44570987/talphera-q4-2024-gaap-eps-0-07-beats-0-16-estimate","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["TLPH"],"gpt_icon":0},{"id":"2523926373","title":"Talphera to Reduce Size of Renal Replacement Therapy Study, Enters Private Placement; Shares Fall","url":"https://stock-news.laohu8.com/highlight/detail?id=2523926373","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2523926373?lang=en_us&edition=fundamental","pubTime":"2025-03-31 22:59","pubTimestamp":1743433184,"startTime":"0","endTime":"0","summary":"Talphera  said Monday it has entered an agreement with the US Food and Drug Administration to reduce the size of a study evaluating patients undergoing renal replacement therapy to 70 patients from 166 that were previously included in the study protocol.The company also said it entered into agreements with institutional investors and a company executive for a private placement of common stock and pre-funded warrants, potentially raising up to $14.8 million.The private placement includes three closings -- the first will raise $4.925 million on April 2, the second and third closings are contingent on milestones, including enrolling at least 17 and 35 patients in the study, and meeting stock price requirements. In total, Talphera said it plans to issue up to about 3.4 million common shares and nearly 5 million pre-funded warrants at $0.586 per share and $0.585 per warrant.Shares of Talphera were down 13% in recent trading activity.Price: 0.51, Change: -0.08, Percent Change: -12.97","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4007","TLPH"],"gpt_icon":0},{"id":"2523876949","title":"Talphera Inc - Talphera Believes Nephro Crrt Study Should Be Completed by End of 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2523876949","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2523876949?lang=en_us&edition=fundamental","pubTime":"2025-03-31 20:30","pubTimestamp":1743424210,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250331:nFWN3QE1E6:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4007","TLPH"],"gpt_icon":0},{"id":"2523498739","title":"Talphera Announces Agreement With the FDA to Reduce the Nephro Crrt Study Size to 70 Patients From 166 and a Private Placement Financing Priced at-the Market of up to $14.8 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2523498739","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2523498739?lang=en_us&edition=fundamental","pubTime":"2025-03-31 20:30","pubTimestamp":1743424210,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250331:nFWN3QE1E6:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4007","TLPH"],"gpt_icon":0},{"id":"2519877814","title":"Talphera Inc  expected to post a loss of 16 cents a share - Earnings Preview","url":"https://stock-news.laohu8.com/highlight/detail?id=2519877814","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2519877814?lang=en_us&edition=fundamental","pubTime":"2025-03-14 19:11","pubTimestamp":1741950665,"startTime":"0","endTime":"0","summary":"Talphera Inc  expected to post a loss of16cents a share - Earnings Preview Talphera Inc TLPH.OQ TLPH.O is expected to show a fall in quarterly revenue when it reports  results on March 17 (estimated) ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250314:nL8N3PX0TC:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["TLPH"],"gpt_icon":0},{"id":"2514334703","title":"Talphera Inc  expected to post a loss of 16 cents a share - Earnings Preview","url":"https://stock-news.laohu8.com/highlight/detail?id=2514334703","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514334703?lang=en_us&edition=fundamental","pubTime":"2025-02-28 19:22","pubTimestamp":1740741741,"startTime":"0","endTime":"0","summary":"Talphera Inc  expected to post a loss of16cents a share - Earnings Preview Talphera Inc TLPH.OQ TLPH.O is expected to show a fall in quarterly revenue when it reports  results on March 4 (estimated) f","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250228:nL5N3PJ0YI:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["TLPH"],"gpt_icon":0},{"id":"2503095578","title":"Talphera reaches agreement with FDA in Nephro CRRT study","url":"https://stock-news.laohu8.com/highlight/detail?id=2503095578","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2503095578?lang=en_us&edition=fundamental","pubTime":"2025-01-14 21:35","pubTimestamp":1736861750,"startTime":"0","endTime":"0","summary":"Talphera (TLPH) announced that following a meeting with the FDA, the agency has agreed to review a Prior Approval Supplement requesting a reduction...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/talphera-reaches-agreement-with-fda-in-nephro-crrt-study?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/talphera-reaches-agreement-with-fda-in-nephro-crrt-study?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["TLPH","BK4007"],"gpt_icon":0},{"id":"2503578441","title":"BRIEF-Talphera Announces Agreement With The FDA For Prior Approval Supplement Review To Reduce The Number Of Patients In The the NEPHRO CRRT Study","url":"https://stock-news.laohu8.com/highlight/detail?id=2503578441","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2503578441?lang=en_us&edition=fundamental","pubTime":"2025-01-14 21:31","pubTimestamp":1736861470,"startTime":"0","endTime":"0","summary":"Jan 14  - Talphera Inc   :   * TALPHERA ANNOUNCES AGREEMENT WITH THE FDA FOR PRIOR APPROVAL SUPPLEMENT REVIEW TO REDUCE THE NUMBER OF PATIENTS IN THE NEPHRO CRRT STUDY   * TALPHERA INC: FDA AGREED TO TWO ADDITIONAL PROTOCOL CHANGES EXPECTED TO ACCELERATE ENROLLMENT IN NEPHRO CRRT STUDYSource text:    Further company coverage:    ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"BRIEF-Talphera Announces Agreement With The FDA For Prior Approval Supplement Review To Reduce The Number Of Patients In The the NEPHRO CRRT Study","news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","TLPH"],"gpt_icon":0},{"id":"2503781165","title":"Talphera Inc: FDA Agreed to Two Additional Protocol Changes Expected to Accelerate Enrollment in Nephro Crrt Study","url":"https://stock-news.laohu8.com/highlight/detail?id=2503781165","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2503781165?lang=en_us&edition=fundamental","pubTime":"2025-01-14 21:30","pubTimestamp":1736861411,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250114:nFWN3OA0D1:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["TLPH","BK4007"],"gpt_icon":0},{"id":"2503781455","title":"Talphera Announces Agreement With the FDA for Prior Approval Supplement Review to Reduce the Number of Patients in the Nephro Crrt Study","url":"https://stock-news.laohu8.com/highlight/detail?id=2503781455","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2503781455?lang=en_us&edition=fundamental","pubTime":"2025-01-14 21:30","pubTimestamp":1736861406,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250114:nTUAG0L9L:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["TLPH","BK4007"],"gpt_icon":0},{"id":"2503957305","title":"Talphera Announces Agreement with the FDA for Prior Approval Supplement Review to Reduce the Number of Patients in the NEPHRO CRRT Study","url":"https://stock-news.laohu8.com/highlight/detail?id=2503957305","media":"PR Newswire","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2503957305?lang=en_us&edition=fundamental","pubTime":"2025-01-14 21:30","pubTimestamp":1736861400,"startTime":"0","endTime":"0","summary":"Submission of a Prior Approval Supplement for a reduction in the number of patients in the NEPHRO CRRT study is expected within the coming week. The FDA agreed to two additional protocol changes expected to accelerate enrollment in the NEPHRO CRRT study. SAN MATEO, Calif., Jan. 14, 2025 /PRNewswire/ --Talphera, Inc. , , a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use in medically supervised settings, today announced that following a meeting with the U.S. Food and Drug Administration , the agency has agreed to review a Prior Approval Supplement  requesting a reduction in the number of patients in the NEPHRO CRRT clinical study. A PAS is reviewed by the FDA within 30 days, and its approval by the agency is required before formally amending the study protocol.Talphera, Inc. is a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use in medically supervised setting","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"yahoofinance","url":"https://finance.yahoo.com/news/talphera-announces-agreement-fda-prior-133000407.html","rn_cache_url":null,"customStyle":"img, svg { display: none !important; }","selectors":"article","filters":"","directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/talphera-announces-agreement-fda-prior-133000407.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["TLPH","ARDS","BK4139","IDE","BK4007"],"gpt_icon":0},{"id":"2490813491","title":"Talphera Inc - Receives Notice of Non-Compliance With Nasdaq Minimum Bid Price Requirement","url":"https://stock-news.laohu8.com/highlight/detail?id=2490813491","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2490813491?lang=en_us&edition=fundamental","pubTime":"2024-12-12 05:34","pubTimestamp":1733952851,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241211:nFWN3NC1S4:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4007","TLPH"],"gpt_icon":0},{"id":"2487651615","title":"BRIEF-Talphera Receives Notice Of Non-Compliance With Nasdaq Equity Requirement","url":"https://stock-news.laohu8.com/highlight/detail?id=2487651615","media":"Reuters","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2487651615?lang=en_us&edition=fundamental","pubTime":"2024-11-30 07:13","pubTimestamp":1732922037,"startTime":"0","endTime":"0","summary":"BRIEF-Talphera Receives Notice Of Non-Compliance With Nasdaq Equity RequirementNov 29  - Talphera Inc TLPH.O:TALPHERA INC - RECEIVES NOTICE OF NON-COMPLIANCE WITH NASDAQ EQUITY REQUIREMENTSource text: [ID:n0001437749-24-036376]Further company coverage: TLPH.O ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241129:nFWN3N00FX:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["TLPH","BK4007"],"gpt_icon":0},{"id":"2487590897","title":"Talphera Inc - Receives Notice of Non-Compliance With Nasdaq Equity Requirement","url":"https://stock-news.laohu8.com/highlight/detail?id=2487590897","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2487590897?lang=en_us&edition=fundamental","pubTime":"2024-11-30 05:32","pubTimestamp":1732915955,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241129:nFWN3N00FX:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4007","TLPH"],"gpt_icon":0},{"id":"2486743102","title":"Press Release: Ascentage Pharma Appoints Ms. Marina S. Bozilenko and Dr. Debra Yu as Independent Non-Executive Directors","url":"https://stock-news.laohu8.com/highlight/detail?id=2486743102","media":"Dow Jones","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2486743102?lang=en_us&edition=fundamental","pubTime":"2024-11-25 08:27","pubTimestamp":1732494420,"startTime":"0","endTime":"0","summary":"ROCKVILLE, Md. and SUZHOU, China, Nov. 24, 2024 /PRNewswire/ -- Ascentage Pharma , a global biopharmaceutical company engaged in discovering, developing and commercializing therapies to address global unmet medical needs primarily for malignancies, today announced that it has appointed Ms. Marina S. Bozilenko and Dr. Debra Yu as additional independent non-executive directors of the company with effect from November 25, 2024.\"I would like to extend a warm welcome to Ms. Marina S. Bozilenko and Dr. Debra Yu, who are joining Ascentage Pharma as independent non-executive directors,\" said Dr. Dajun Yang, Chairman & CEO of Ascentage Pharma. \"Both Ms. Bozilenko and Dr. Yu are accomplished industry veterans possessing a wealth of experience in the finance, investment, business development, and strategic management in the global biopharmaceutical sector. Ascentage Pharma is currently at a crucial stage of its development where we are making further strides with our global innovation strategy. W","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0456855351.SGD","SQQQ","LU1720051108.HKD",".IXIC","LU0225771236.USD","MGTX","LU1363072403.SGD","MNQmain","OLMA","LU0098860793.USD","06855","LU1548497426.USD","LU0306806265.USD","BK4592","BK4017","LU2271345857.HKD","BK4585","QLD","LU0868494617.USD","LU2357305700.SGD","BK1574","BK4534","LU0170899867.USD","LU1720051017.SGD","QID","LU0106831901.USD","TLPH","IE00B19Z3581.USD","LU1057294990.SGD","CDE","NQmain","BK4581","SG9999001176.SGD","TQQQ","LU0006306889.USD","BK4568","LU1989772840.SGD","PSQ","LU1066051498.USD","BK4533","LU1894683348.USD","LU2089284900.SGD","LIAN","BK4550","IE00BLSP4239.USD","IE000M9KFDE8.USD","LU1023059063.AUD"],"gpt_icon":1},{"id":"2483519572","title":"Talphera Third Quarter 2024 Earnings: US$0.13 loss per share (vs US$0.085 loss in 3Q 2023)","url":"https://stock-news.laohu8.com/highlight/detail?id=2483519572","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2483519572?lang=en_us&edition=fundamental","pubTime":"2024-11-16 21:14","pubTimestamp":1731762862,"startTime":"0","endTime":"0","summary":"NasdaqGM:TLPH Earnings and Revenue History November 16th 2024. All figures shown in the chart above are for the trailing 12 month  period. Looking ahead, revenue is forecast to grow 75% p.a. on average during the next 3 years, compared to a 10% growth forecast for the Pharmaceuticals industry in the US.The company's shares are down 24% from a week ago.Before we wrap up, we've discovered 5 warning signs for Talphera (2 can't be ignored!","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/5Vpve0Pc2F3m_L3fs2p_dQ--~B/aD02MzY7dz05NDU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/simply_wall_st__316/78a8c60a6283aea0450523395306d38c","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/5Vpve0Pc2F3m_L3fs2p_dQ--~B/aD02MzY7dz05NDU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/simply_wall_st__316/78a8c60a6283aea0450523395306d38c"],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/talphera-third-quarter-2024-earnings-131422209.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["TLPH"],"gpt_icon":0}],"pageSize":20,"totalPage":2,"pageCount":1,"totalSize":25,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/TLPH\",params:#limit:5,,,undefined,":[{"market":"US","date":"2025-03-31","symbol":"TLPH","fiscalQuarterEnding":"2024/12","expectedEps":-0.21,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1743393600000,"reportTimeType":"post","actualEps":-0.07},{"market":"US","date":"2024-11-13","symbol":"TLPH","fiscalQuarterEnding":"2024/09","expectedEps":-0.2,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1731474000000,"reportTimeType":"post","actualEps":-0.13},{"market":"US","date":"2024-08-14","symbol":"TLPH","fiscalQuarterEnding":"2024/06","expectedEps":-0.22,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1723608000000,"reportTimeType":"post","actualEps":-0.15},{"market":"US","date":"2024-05-14","symbol":"TLPH","fiscalQuarterEnding":"2024/03","expectedEps":-0.28,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1715659200000,"reportTimeType":"post","actualEps":-0.16},{"market":"US","date":"2024-03-06","symbol":"TLPH","fiscalQuarterEnding":"2023/12","expectedEps":-0.24,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1709701200000,"reportTimeType":"post","actualEps":-0.25}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"TLPH\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"TLPH\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0,"buy":1,"hold":0,"sell":0,"strongSell":0,"meanLabel":"BUY","meanPercent":1,"analysts":3,"updateTime":1715054400000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/TLPH\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"TLPH","date":"2025-04-25","current":-0.637835,"percent":0.891089,"low":-1.454079,"twenty":-1.122064,"median":-0.950724,"eighty":-0.677643,"high":-0.538589,"avg":-0.918177,"sd":0.21978,"marketCap":8294407},"quantilePoints":[{"date":"2024-01-12","current":-0.709783,"twenty":-0.709783,"median":-0.709783,"eighty":-0.709783,"marketCap":15163804},{"date":"2024-01-19","current":-0.768899,"twenty":-0.721606,"median":-0.626863,"eighty":-0.622514,"marketCap":16426748},{"date":"2024-01-26","current":-0.825237,"twenty":-0.834759,"median":-0.716726,"eighty":-0.626609,"marketCap":17630359},{"date":"2024-02-02","current":-0.833172,"twenty":-0.841107,"median":-0.817302,"eighty":-0.683994,"marketCap":17799882},{"date":"2024-02-09","current":-0.682417,"twenty":-0.826824,"median":-0.749854,"eighty":-0.688766,"marketCap":14579166},{"date":"2024-02-16","current":-0.817314,"twenty":-0.826824,"median":-0.768899,"eighty":-0.696692,"marketCap":17461094},{"date":"2024-02-23","current":-1.047431,"twenty":-0.872852,"median":-0.817302,"eighty":-0.705181,"marketCap":22377325},{"date":"2024-03-01","current":-1.079172,"twenty":-0.991886,"median":-0.817314,"eighty":-0.710598,"marketCap":23055425},{"date":"2024-03-08","current":-1.045883,"twenty":-1.042051,"median":-0.825237,"eighty":-0.718658,"marketCap":19241109},{"date":"2024-03-15","current":-1.051518,"twenty":-1.046502,"median":-0.872847,"eighty":-0.724723,"marketCap":19344777},{"date":"2024-03-22","current":-1.03307,"twenty":-1.051518,"median":-0.952196,"eighty":-0.737703,"marketCap":19005395},{"date":"2024-03-28","current":-1.014623,"twenty":-1.051518,"median":-0.991886,"eighty":-0.749061,"marketCap":18666013},{"date":"2024-04-05","current":-1.014623,"twenty":-1.051518,"median":-0.977516,"eighty":-0.759853,"marketCap":18666013},{"date":"2024-04-12","current":-1.051518,"twenty":-1.060742,"median":-0.991886,"eighty":-0.78826,"marketCap":19344777},{"date":"2024-04-19","current":-0.95928,"twenty":-1.057052,"median":-0.989418,"eighty":-0.817302,"marketCap":17647867},{"date":"2024-04-26","current":-1.03307,"twenty":-1.051518,"median":-0.968081,"eighty":-0.817307,"marketCap":19005395},{"date":"2024-05-03","current":-0.942156,"twenty":-1.051518,"median":-0.955738,"eighty":-0.817314,"marketCap":17332836},{"date":"2024-05-10","current":-0.942156,"twenty":-1.051518,"median":-0.951392,"eighty":-0.817314,"marketCap":17332836},{"date":"2024-05-17","current":-1.376289,"twenty":-1.051518,"median":-0.951439,"eighty":-0.820483,"marketCap":19541923},{"date":"2024-05-24","current":-1.244644,"twenty":-1.066276,"median":-0.95928,"eighty":-0.825237,"marketCap":17672696},{"date":"2024-05-31","current":-1.220708,"twenty":-1.07919,"median":-0.968081,"eighty":-0.826824,"marketCap":17332836},{"date":"2024-06-07","current":-1.172597,"twenty":-1.105016,"median":-0.989418,"eighty":-0.838101,"marketCap":16649701},{"date":"2024-06-14","current":-1.172837,"twenty":-1.162665,"median":-0.991886,"eighty":-0.857817,"marketCap":16653117},{"date":"2024-06-21","current":-0.989731,"twenty":-1.167223,"median":-0.991886,"eighty":-0.86955,"marketCap":14053191},{"date":"2024-06-28","current":-1.089063,"twenty":-1.169518,"median":-0.998642,"eighty":-0.872556,"marketCap":15463609},{"date":"2024-07-05","current":-1.101031,"twenty":-1.166458,"median":-1.010011,"eighty":-0.872847,"marketCap":15633538},{"date":"2024-07-12","current":-1.078532,"twenty":-1.162665,"median":-1.014623,"eighty":-0.872847,"marketCap":15314070},{"date":"2024-07-15","current":-1.112999,"twenty":-1.155488,"median":-1.023092,"eighty":-0.872849,"marketCap":15803468},{"date":"2024-08-02","current":-1.11611,"twenty":-1.148312,"median":-1.031561,"eighty":-0.872852,"marketCap":15847650},{"date":"2024-08-09","current":-1.1495,"twenty":-1.140413,"median":-1.03307,"eighty":-0.881601,"marketCap":16321754},{"date":"2024-08-16","current":-1.082672,"twenty":-1.150506,"median":-1.03307,"eighty":-0.89914,"marketCap":14783889},{"date":"2024-08-23","current":-1.12013,"twenty":-1.150506,"median":-1.041541,"eighty":-0.908733,"marketCap":15295378},{"date":"2024-08-30","current":-1.214584,"twenty":-1.160535,"median":-1.047431,"eighty":-0.91316,"marketCap":16585145},{"date":"2024-09-06","current":-1.256895,"twenty":-1.172134,"median":-1.051518,"eighty":-0.91362,"marketCap":17162906},{"date":"2024-09-13","current":-1.120006,"twenty":-1.172789,"median":-1.052339,"eighty":-0.917105,"marketCap":15293679},{"date":"2024-09-20","current":-1.171526,"twenty":-1.172383,"median":-1.060742,"eighty":-0.925267,"marketCap":15997188},{"date":"2024-09-27","current":-1.007507,"twenty":-1.171277,"median":-1.062038,"eighty":-0.931608,"marketCap":13757514},{"date":"2024-10-04","current":-0.983116,"twenty":-1.169518,"median":-1.060742,"eighty":-0.932246,"marketCap":13424451},{"date":"2024-10-11","current":-0.995561,"twenty":-1.165699,"median":-1.055876,"eighty":-0.935347,"marketCap":13594381},{"date":"2024-10-18","current":-1.443563,"twenty":-1.165699,"median":-1.051518,"eighty":-0.938196,"marketCap":19711853},{"date":"2024-10-25","current":-1.193428,"twenty":-1.172383,"median":-1.059667,"eighty":-0.940832,"marketCap":16296264},{"date":"2024-10-31","current":-1.145268,"twenty":-1.175829,"median":-1.062038,"eighty":-0.940832,"marketCap":15638636},{"date":"2024-11-08","current":-1.120006,"twenty":-1.172837,"median":-1.065997,"eighty":-0.942156,"marketCap":15293679},{"date":"2024-11-15","current":-0.718871,"twenty":-1.172597,"median":-1.067654,"eighty":-0.942156,"marketCap":11251050},{"date":"2024-11-22","current":-0.759152,"twenty":-1.171526,"median":-1.065128,"eighty":-0.934799,"marketCap":11881489},{"date":"2024-11-29","current":-0.769204,"twenty":-1.170532,"median":-1.060742,"eighty":-0.922038,"marketCap":12038805},{"date":"2024-12-06","current":-0.744233,"twenty":-1.169884,"median":-1.055876,"eighty":-0.903567,"marketCap":11647985},{"date":"2024-12-13","current":-0.714964,"twenty":-1.167123,"median":-1.051518,"eighty":-0.872774,"marketCap":11189899},{"date":"2024-12-20","current":-0.671877,"twenty":-1.163424,"median":-1.049475,"eighty":-0.831585,"marketCap":10515542},{"date":"2024-12-27","current":-0.54947,"twenty":-1.159469,"median":-1.044734,"eighty":-0.819817,"marketCap":8599755},{"date":"2025-01-03","current":-0.642064,"twenty":-1.157339,"median":-1.038589,"eighty":-0.817307,"marketCap":10048941},{"date":"2025-01-10","current":-0.632054,"twenty":-1.156244,"median":-1.034537,"eighty":-0.816045,"marketCap":9892272},{"date":"2025-01-17","current":-0.674597,"twenty":-1.151726,"median":-1.03307,"eighty":-0.770977,"marketCap":10558115},{"date":"2025-01-24","current":-0.772522,"twenty":-1.151176,"median":-1.031561,"eighty":-0.769204,"marketCap":12090744},{"date":"2025-01-31","current":-0.761424,"twenty":-1.1495,"median":-1.014623,"eighty":-0.766969,"marketCap":11917046},{"date":"2025-02-07","current":-0.750761,"twenty":-1.145268,"median":-1.008005,"eighty":-0.759152,"marketCap":11750160},{"date":"2025-02-14","current":-0.686565,"twenty":-1.145019,"median":-1.005399,"eighty":-0.750761,"marketCap":10745436},{"date":"2025-02-21","current":-0.665892,"twenty":-1.145019,"median":-0.995934,"eighty":-0.743362,"marketCap":10421881},{"date":"2025-02-28","current":-0.62879,"twenty":-1.144322,"median":-0.991886,"eighty":-0.729,"marketCap":9841185},{"date":"2025-03-07","current":-0.555931,"twenty":-1.135885,"median":-0.989659,"eighty":-0.722709,"marketCap":8700874},{"date":"2025-03-14","current":-0.614754,"twenty":-1.13372,"median":-0.983614,"eighty":-0.709274,"marketCap":9621508},{"date":"2025-03-21","current":-0.670245,"twenty":-1.132699,"median":-0.983116,"eighty":-0.695334,"marketCap":10489998},{"date":"2025-03-28","current":-0.674597,"twenty":-1.130559,"median":-0.968503,"eighty":-0.691179,"marketCap":10558115},{"date":"2025-04-04","current":-0.746305,"twenty":-1.128493,"median":-0.963783,"eighty":-0.690853,"marketCap":9704951},{"date":"2025-04-11","current":-0.644804,"twenty":-1.127045,"median":-0.958352,"eighty":-0.685651,"marketCap":8385028},{"date":"2025-04-17","current":-0.606147,"twenty":-1.125692,"median":-0.951485,"eighty":-0.684843,"marketCap":7882337},{"date":"2025-04-25","current":-0.637835,"twenty":-1.122064,"median":-0.950724,"eighty":-0.677643,"marketCap":8294407}],"updateTime":1745836793706}}}